Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.
- DOI
- 10.1093/ibd/izag055
- Published
- 2026 Sep 1
- Container
- Inflammatory bowel diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ibd/izag055,
title = {Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.},
author = {Afzali A and Danese S and Panaccione R and Rubin DT and Sands BE and Reinisch W and Panés J and Van Rampelbergh R and Terry NA and Salese L and Vetter ML and Yee J and Corbett C and van Duijnhoven W and Hisamatsu T and Andrews JM and D'Haens GR and GALAXI 1 investigators},
year = {2026},
journal = {Inflammatory bowel diseases},
doi = {10.1093/ibd/izag055},
url = {https://doi.org/10.1093/ibd/izag055}
}RIS
TY - JOUR TI - Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial. AU - Afzali A AU - Danese S AU - Panaccione R AU - Rubin DT AU - Sands BE AU - Reinisch W AU - Panés J AU - Van Rampelbergh R AU - Terry NA AU - Salese L AU - Vetter ML AU - Yee J AU - Corbett C AU - van Duijnhoven W AU - Hisamatsu T AU - Andrews JM AU - D'Haens GR AU - GALAXI 1 investigators PY - 2026 JO - Inflammatory bowel diseases DO - 10.1093/ibd/izag055 UR - https://doi.org/10.1093/ibd/izag055 ER -
APA
A, A., S, D., R, P., DT, R., BE, S., W, R., J, P., R, V. R., NA, T., L, S., ML, V., J, Y., C, C., W, V. D., T, H., JM, A., GR, D., & investigators, G. 1. (2026). Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial.. Inflammatory bowel diseases. https://doi.org/10.1093/ibd/izag055
Source records
- pubmed · retrieved 2026-09-26T00:11:02.140Z